Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by cognitive impairment, attention deficit, hyperactivity, anxiety, unstable mood, autistic behaviors, language delay, and seizures (Hagerman et al., 2010). This X-linked chromosome disorder is the most common known cause of autism with 30% of boys meeting full autism criteria (Harris et al., 2008). In the majority of cases, FXS is caused by a trinucleotide repeat expansion (CGG) in the FMR1 gene, which causes loss of expression of fragile X mental retardation protein (FMRP) (Santoro et al., 2011). FMRP is an RNA binding protein that plays a critical role in synaptic protein synthesis. There are medications for managing symptoms of FXS, but there are no disease specific therapies and no cure.
The main challenges confronting the FXS field include early diagnosis, validating outcome measures for clinical trials, and identifying viable treatment targets. In terms of early diagnosis, population wide screening is feasible. Recent advances in FMR1 allele analysis allow rapid and inexpensive assessment of CGG repeat size, the number of AGG interruptions, and methylation status from blood or saliva samples (Hayward et al., 2016). However, a FXS genetic test is not included in the newborn screening (NBS) panel in the United States due to ethical debates regarding screening for genetic disorders where no therapeutic intervention exists and contemporaneous identification of premutation carriers. Proponents of FXS NBS argue that screening is needed for early detection and intervention (Tassone, 2014). Numerous disease mechanism-based drugs are in clinical trials for FXS and early intervention may be required for better therapeutic efficacy. Preliminary results indicate that babies with FMR1 premutations exhibit an altered developmental trajectory on measures of nonverbal communication and hyperresponsivity to sensory experiences (Wheeler et al., 2016). Thus, early diagnosis could benefit both full and premutation carriers.
With regard to the urgent need to validate outcome measures for FXS clinical trials, recent trials failed on primary endpoints (Berry-Kravis et al., 2013, 2016). Soluble amyloid precursor protein alpha (sAPPĪ±) is elevated in plasma of autistic children and can be detected in human umbilical cord blood supporting feasibility of this APP metabolite as an early diagnostic autism biomarker (Sokol et al., 2006; Bailey et al., 2008). APP metabolites are also altered in FXS (Westmark et al., 2016), and a recent trial with acamprosate indicates that sAPPĪ± is responsive to drug treatment (Erickson et al., 2014).
Concerning identification of viable treatment targets, excessive signaling through metabotropic glutamate receptor 5 (mGluR5) leads to increased translation of numerous synaptic proteins and altered plasticity in FXS (Bear et al., 2004). Many of these proteins are under investigation as potential FXS drug targets. Of relevance herein, two overexpressed proteins are APP and amyloid-beta (Westmark and Malter, 2007), which have been well-studied in Alzheimer's disease (AD). Accumulating evidence suggests that dysregulated levels of APP metabolites contribute to FXS pathology (Figure 1), supporting the hypothesis that pharmaceuticals under study for modulation of APP and amyloid-beta in AD may be viable therapeutic strategies for FXS (Westmark et al., 2013; Pasciuto et al., 2015).
Figure 1
In their Stem Cells article, Khalfallah and colleagues report the development of a mouse embryonic stem cell (mESC)-based FXS disease model. Specifically, they generated an isogenic stable cell line by targeted knockdown of the Fmr1 gene with a short hairpin (sh)RNA, and used this model to demonstrate that decreased expression of FMRP triggers accelerated differentiation of neurons and elevated expression of the transcription factor Ascl1/Mash1 and the membrane glycoprotein APP (Khalfallah et al., 2017). Fmr1 mRNA and protein levels were specifically and significantly reduced in shFmr1 mESC compared to control cells while expression of FMRP homologs was unaffected. Fmr1 knockdown did not alter mESC morphology or proliferation; however, there was premature generation of neural progenitors as evidenced by a rosette-like morphology at 4 days in vitro and altered expression of neuro-specific markers. The authors confirmed that neurogenesis was accelerated in vivo in Fmr1KO mouse embryonic brain. They further showed that accelerated neurogenesis in the shFmr1 mESC model was rescued by genetic introduction of the human FMR1 gene or pharmacological treatment with BACE-1 inhibitor LY2811376.
Neurogenesis is the process through which neurons are generated from neural stem and progenitor cells. Both FMRP and APP have evolutionarily conserved roles in regulating embryonic and adult neurogenesis (Hayashi et al., 1994; Ohsawa et al., 1999; Caille et al., 2004; Callan et al., 2010; Luo et al., 2010; Demars et al., 2011; Nicolas and Hassan, 2014; Wang et al., 2014, 2016; Faulkner et al., 2015; Halevy et al., 2015). FMRP regulates the translation of both Ascl1 (Fahling et al., 2009) and APP (Westmark and Malter, 2007; Lee et al., 2010). Ascl1 is involved in the transcriptional regulation of genes associated with all major steps of neurogenesis (Castro et al., 2011). APP expression, trafficking, and processing are dynamically regulated during neuronal differentiation (Bergstrom et al., 2016; Ramaker et al., 2016). The APP metabolite amyloid-beta upregulates expression of Ascl1 (Uchida et al., 2007) and drives the differentiation of progenitor cells toward a neuronal lineage (Calafiore et al., 2006). Thus, defective crosstalk among Asc1 and APP metabolites in the absence of FMRP likely contributes to accelerated neurogenesis in FXS. Early interventions targeted at normalizing this signaling pathway could promote normal brain development.
The shFmr1 mESC model developed by the Bardoni laboratory overcomes the inherent ethical and scientific problems associated with human FMR1 embryonic stem cells (hESC), most of which carry the methylated and silenced full mutation and/or are mosaic in CGG-repeat length and exhibit residual FMRP expression. In essence, this elegant work addresses the three main challenges of the FXS field by: (1) developing a Fmr1 knockdown stem cell model that allows study of the earliest events of neurogenesis to support NBS and early intervention; (2) identifying a role for APP in the kinetics of neurogenesis, which supports the development of APP metabolites as potential FXS biomarkers; and (3) demonstrating rescue of shFmr1 mESC morphology with a BACE-1 inhibitor thus promoting study of APP and secretases as therapeutic targets for FXS.
Khalfallah and colleagues contribute a vital piece to the FXS puzzle in describing development of a mESC model that allows study of early molecular events underlying disease development and provides a new platform for preclinical drug testing. Substantial data is provided validating the morphological and molecular characteristics of the shFmr1 mESC as well as demonstrating rescue of phenotypes by re-introduction of FMRP or by targeting APP processing via inhibition of BACE-1. Future experiments could examine expression of various APP metabolites on neurogenesis, compare BACE-1 and mGluR5 inhibitors, confirm FXS signaling pathways in this early disease-stage model, and transfect plasmids carrying varying length CGG repeats in the human FMR1 gene to mimic the repeat expansion aspect of the disorder.
Statements
Author contributions
The author confirms being the sole contributor of this work and approved it for publication.
Acknowledgments
CW was supported by FRAXA Research Foundation and the Department of Defense (W81XWH-16-1-0082).
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BaileyA. R.GiuntaB. N.ObregonD.NikolicW. V.TianJ.SanbergC. D.et al. (2008). Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int. J. Clin. Exp. Med.1, 338ā344.
2
BearM. F.HuberK. M.WarrenS. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci.27, 370ā377. 10.1016/j.tins.2004.04.009
3
BergstromP.AgholmeL.NazirF. H.SatirT. M.ToombsJ.WellingtonH.et al. (2016). Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. Sci. Rep.6:29200. 10.1038/srep29200
4
Berry-KravisE.Des PortesV.HagermanR.JacquemontS.CharlesP.VisootsakJ.et al. (2016). Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med.8:321ra5. 10.1126/scitranslmed.aab4109
5
Berry-KravisE.HesslD.AbbedutoL.ReissA. L.Beckel-MitchenerA.UrvT. K.et al. (2013). Outcome measures for clinical trials in fragile X syndrome. J. Dev. Behav. Pediatr.34, 508ā522. 10.1097/DBP.0b013e31829d1f20
6
CailleI.AllinquantB.DupontE.BouillotC.LangerA.MullerU.et al. (2004). Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development131, 2173ā2181. 10.1242/dev.01103
7
CalafioreM.BattagliaG.ZappalaA.Trovato-SalinaroE.CaraciF.CarusoM.et al. (2006). Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid. Neurobiol. Aging27, 606ā613. 10.1016/j.neurobiolaging.2005.03.019
8
CallanM. A.CabernardC.HeckJ.LuoisS.DoeC. Q.ZarnescuD. C. (2010). Fragile X protein controls neural stem cell proliferation in the Drosophila brain. Hum. Mol. Genet.19, 3068ā3079. 10.1093/hmg/ddq213
9
CastroD. S.MartynogaB.ParrasC.RameshV.PacaryE.JohnstonC.et al. (2011). A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. Genes Dev.25, 930ā945. 10.1101/gad.627811
10
DemarsM. P.BartholomewA.StrakovaZ.LazarovO. (2011). Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res. Ther.2:36. 10.1186/scrt77
11
EricksonC. A.RayB.MaloneyB.WinkL. K.BowersK.SchaeferT. L.et al. (2014). Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J. Psychiatr. Res.59, 220ā228. 10.1016/j.jpsychires.2014.07.011
12
FahlingM.MrowkaR.SteegeA.KirschnerK. M.BenkoE.ForsteraB.et al. (2009). Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J. Biol. Chem.284, 4255ā4266. 10.1074/jbc.M807354200
13
FaulknerR. L.WishardT. J.ThompsonC. K.LiuH. H.ClineH. T. (2015). FMRP regulates neurogenesis in vivo in Xenopus laevis tadpoles. eNeuro2:e0055. 10.1523/ENEURO.0055-14.2014
14
HagermanR.HoemG.HagermanP. (2010). Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol. Autism1:12. 10.1186/2040-2392-1-12
15
HalevyT.CzechC.BenvenistyN. (2015). Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports4, 37ā46. 10.1016/j.stemcr.2014.10.015
16
HarrisS. W.HesslD.Goodlin-JonesB.FerrantiJ.BacalmanS.BarbatoI.et al. (2008). Autism profiles of males with fragile X syndrome. Am. J. Ment. Retard.113, 427ā43810.1352/2008.113:427-438
17
HayashiY.KashiwagiK.OhtaJ.NakajimaM.KawashimaT.YoshikawaK. (1994). Alzheimer amyloid protein precursor enhances proliferation of neural stem cells from fetal rat brain. Biochem. Biophys. Res. Commun.205, 936ā943. 10.1006/bbrc.1994.2755
18
HaywardB. E.ZhouY.KumariD.UsdinK. (2016). A set of assays for the comprehensive analysis of fMR1 alleles in the Fragile X-related disorders. J. Mol. Diagn.18, 762ā77410.1016/j.jmoldx.2016.06.001
19
HuberK. M.GallagherS. M.WarrenS. T.BearM. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U.S.A.99, 7746ā7750. 10.1073/pnas.122205699
20
KhalfallahO.JarjatM.DavidovicL.NottetN.CesteleS.MantegazzaM.et al. (2017). Depletion of the fragile X mental retardation protein in embryonic stem cells alters the kinetics of neurogenesis. Stem Cells35, 374ā385. 10.1002/stem.2505
21
LeeE. K.KimH. H.KuwanoY.AbdelmohsenK.SrikantanS.SubaranS. S.et al. (2010). hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat. Struct. Mol. Biol.17, 732ā739. 10.1038/nsmb.1815
22
LiaoL.ParkS. K.XuT.VanderklishP.YatesJ. R.III (2008). Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc. Natl. Acad. Sci. U.S.A.105, 15281ā15286. 10.1073/pnas.0804678105
23
LuoY.ShanG.GuoW.SmrtR. D.JohnsonE. B.LiX.et al. (2010). Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet.6:e1000898. 10.1371/journal.pgen.1000898
24
MaloneyB.LahiriD. K. (2011). The Alzheimer's amyloid beta-peptide (Abeta) binds a specific DNA Abeta-interacting domain (AbetaID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif. Gene488, 1ā12. 10.1016/j.gene.2011.06.004
25
Mateu-HuertasE.Rodriguez-RevengaL.Alvarez-MoraM. I.MadrigalI.WillemsenR.MilaM.et al. (2014). Blood expression profiles of fragile X premutation carriers identify candidate genes involved in neurodegenerative and infertility phenotypes. Neurobiol. Dis.65, 43ā54. 10.1016/j.nbd.2013.12.020
26
NicolasM.HassanB. A. (2014). Amyloid precursor protein and neural development. Development141, 2543ā2548. 10.1242/dev.108712
27
OhsawaI.TakamuraC.MorimotoT.IshiguroM.KohsakaS. (1999). Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur. J. Neurosci.11, 1907ā1913. 10.1046/j.1460-9568.1999.00601.x
28
PasciutoE.AhmedT.WahleT.GardoniF.D'AndreaL.PaciniL.et al. (2015). Dysregulated ADAM10-mediated processing of APP during a critical time window leads to synaptic deficits in fragile X syndrome. Neuron87, 382ā398. 10.1016/j.neuron.2015.06.032
29
RamakerJ. M.CargillR. S.SwansonT. L.QuirindongoH.CassarM.KretzschmarD.et al. (2016). Amyloid precursor proteins are dynamically trafficked and processed during neuronal development. Front. Mol. Neurosci.9:130. 10.3389/fnmol.2016.00130
30
RayB.SokolD. K.MaloneyB.LahiriD. K. (2016). Finding novel distinctions between the sAPPalpha-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue. Sci. Rep.6:26052. 10.1038/srep26052
31
RenouxA. J.CarducciN. M.AhmadyA. A.ToddP. K. (2014). Fragile X mental retardation protein expression in Alzheimer's disease. Front. Genet.5:360. 10.3389/fgene.2014.00360
32
SantoroM. R.BrayS. M.WarrenS. T. (2011). Molecular mechanisms of Fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219ā245. 10.1146/annurev-pathol-011811-132457
33
SokolD. K.ChenD.FarlowM. R.DunnD. W.MaloneyB.ZimmerJ. A.et al. (2006). High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J. Child Neurol.21, 444ā449. 10.1146/annurev-pathol-011811-132457
34
TassoneF. (2014). Newborn screening for fragile X syndrome. JAMA Neurol.71, 355ā359. 10.1001/jamaneurol.2013.4808
35
TassoneF.GrecoC. M.HunsakerM. R.SeritanA. L.BermanR. F.GaneL. W.et al. (2012). Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav.11, 577ā585. 10.1111/j.1601-183X.2012.00779.x
36
UchidaY.NakanoS.GomiF.TakahashiH. (2007). Differential regulation of basic helix-loop-helix factors Mash1 and Olig2 by beta-amyloid accelerates both differentiation and death of cultured neural stem/progenitor cells. J. Biol. Chem.282, 19700ā19709. 10.1074/jbc.M703099200
37
WangB.WangZ.SunL.YangL.LiH.ColeA. L.et al. (2014). The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. J. Neurosci.34, 13314ā13325. 10.1523/JNEUROSCI.2848-14.2014
38
WangS.BolosM.ClarkR.CullenC. L.SouthamK. A.FoaL.et al. (2016). Amyloid beta precursor protein regulates neuron survival and maturation in the adult mouse brain. Mol Cell Neurosci77, 21ā33. 10.1016/j.mcn.2016.09.002
39
WestmarkC. J.Berry-KravisE. M.IkonomidouC.YinJ. C.PuglielliL. (2013). Developing BACE-1 inhibitors for FXS. Front Cell Neurosci7:77. 10.3389/fncel.2013.00077
40
WestmarkC. J.MalterJ. S. (2007). FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol5:e52. 10.1371/journal.pbio.0050052
41
WestmarkC. J.SokolD. K.MaloneyB.LahiriD. K. (2016). Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. Mol Psychiatry21, 1333ā1341. 10.1038/mp.2016.134
42
WestmarkC. J.WestmarkP. R.O'RiordanK. J.RayB. C.HerveyC. M.SalamatM. S.et al. (2011). Reversal of Fragile X phenotypes by manipulation of AbPP/Ab levels in Fmr1 mice. PLoS ONE6:e26549. 10.1371/journal.pone.0026549
43
WheelerA. C.SiderisJ.HagermanR.Berry-KravisE.TassoneF.BaileyD. B.et al. (2016). Developmental profiles of infants with an FMR1 premutation. J. Neurodev. Disord.8:40. 10.1186/s11689-016-9171-8
Summary
Keywords
APP, FMRP, fragile X syndrome, secretases, neurogenesis
Citation
Westmark CJ (2017) Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis. Front. Mol. Neurosci. 10:29. doi: 10.3389/fnmol.2017.00029
Received
10 December 2016
Accepted
24 January 2017
Published
07 February 2017
Volume
10 - 2017
Edited by
Regina Dahlhaus, Friedrich Alexander University Erlangen-NĆ¼rnberg, Germany
Reviewed by
Claes Wahlestedt, University of Miami School of Medicine, USA; Corrado Romano, IRCCS Associazione Oasi Maria Santissima, Italy
Updates
Copyright
Ā© 2017 Westmark.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cara J. Westmark westmark@wisc.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.